ClinicalTrials.gg
RecruitingNCT06085313CAIUpdated Oct 30, 2026

Cancer Pain Management Using a Web-based Intervention

An interventional study of CAI and CAPA in Cancer of Breast, Depressive Symptoms and Cancer Pain, sponsored by Vanderbilt University. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Vanderbilt University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2024; still recruiting 2 years 9 months later.
Updated Oct 30, 2026Study completion movedSponsor changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Breast Neoplasms by Vanderbilt University — 1 open to participants now, 1 under way, none of them phase 3. Breast Neoplasms · Vanderbilt University.

Planned enrollment
Largest of 10
300 · median 81
Started
2024
the only one that year
No phase
8 of 12
1 open now
Registered
12th of 12
by date

Among the 12 studies in Breast Neoplasms by Vanderbilt University, this one has the largest planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2024, is one of 8 with no phase, and was the 12th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

1 of the 12 studies in Breast Neoplasms by Vanderbilt University is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Breast Neoplasms by Vanderbilt University, or all of them as a file.
02

Study summary

This study is funded by the HEAL Initiative (https://heal.nih.gov/). Based on Preliminary Studies (PSs), the research team developed and pilot-tested an evidence-based Web App-based information and coaching/support program for cancer pain management (CAPA) that was culturally tailored to Asian American breast cancer survivors using multiple unique features. However, CAPA rarely considered depressive symptoms accompanying pain in its design or components, and PSs indicated the necessity of further individualization of the intervention components of CAPA due to diversities in the needs of ABD. The purpose of the proposed 2-phase study is to further develop CAPA with additional components for ABD and the individual optimization functionality (CAI) and to test the efficacy of CAI in improving cancer pain experience of ABD. The specific aims are to: a) develop and evaluate CAI through an expert review and a usability test (R61 phase); b) determine whether the intervention group (that uses CAI and usual care) will show significantly greater improvements than the active control group (that uses CAPA and usual care) in primary outcomes (cancer pain management and cancer pain experience including depressive symptoms) from baseline to post 1-month and post 3-months; c) identify theory-based variables (attitudes, self-efficacy, perceived barriers, and social influences) that mediate the intervention effects of CAI on the primary outcomes; and d) determine whether the effects of CAI on the primary outcomes are moderated by selected background, disease, genetic, and situational factors. This study is guided by the Bandura's Theory and the stress and coping framework by Lazarus and Folkman. The R61 phase includes: (a) the intervention development process, (b) a usability test among 15 ABD, 15 family members, and 15 community gatekeepers; and (c) an expert review among 10 experts in oncology. The R33 phase adopts a randomized repeated measures control group design among 300 ABD. Long-term goals are: (a) to extend and test CAI in various healthcare settings with diverse subgroups of ABD, (b) examine the costeffectiveness, sustainability, and scalability of CAI in the settings, and (c) translate CAI into health care for ABD.

Read the detailed description

Due to advances in early detection and treatment, breast cancer survivors represent nearly 70% of the 5.6 million female cancer survivors in the U.S. These women usually have some combination of surgery, radiation or chemotherapy, which can result in significant chronic pain. Indeed, the prevalence of pain is much higher in breast cancer survivors compared to survivors of other kinds of cancer. Pain occurs in 25%\~60% of breast cancer survivors and about half report moderate to severe pain. Chronic pain decreases survivors' quality of life and daily functioning, and increases their fatigue, depression, anxiety, and sleep disruption.

Racial/ethnic minorities are high-risk groups for inadequate pain management. Racial/ethnic minority patients in the U.S. tend to present with a later-stage disease than non-minority patients, and their pain is more likely to be undertreated. Specifically, Asian Americans reportedly shoulder unnecessary burden of pain because they rarely complain, delay seeking help, and rarely ask necessary information or support due to cultural values, beliefs, and language barriers. Because of their cultural stigma attached to breast cancer, fear of addiction to pain medication, and stoicism toward pain, they tend to unnecessarily tolerate pain that they could easily manage with currently existing regimen including pharmacologic and non-pharmacologic strategies.

Especially, Asian American breast cancer survivors with depressive symptoms (ABD) are more likely to suffer from inadequate pain management due to their depression (e.g., not motivated enough to seek for help, stigma attached to depression), and pain could also worsen their depressive symptoms. Indeed, depression is a common co-morbidity in breast cancer survivors. A systematic literature review indicated that Asian American breast cancer survivors had moderate to high levels of depressive symptoms, anxiety and post-traumatic stress symptoms. In another study among 1,400 Chinese breast cancer survivors, about 26% had mild to severe depression and 13% fulfilled the criteria of clinical depression. Furthermore, as mentioned above, the recent opioid crisis has exacerbated their fear of addiction and reluctance to seek help. The Coronavirus Disease 2019 (COVID19) pandemic with Anti-Asian incidents has also placed an additional dimension of stress to this population.

Despite systematic efforts to provide adequate cancer pain management, researchers continue to find barriers including patients' beliefs and misconceptions, meanings of cancer pain, expectations about pain relief, miscommunication, lack of social support, inadequate training of healthcare providers and deficiencies within the healthcare infrastructure (e.g., insurance coverage). Among these, this study focuses on those at the individual and interpersonal levels of influence (by the National Institute of Minority Health and Health Disparity (NIMHD) Research Framework) as the first step.

Technology-based programs could be a solution to fill this gap in care for the survivors in communities. Mainly because of easy access (e.g., no transportation required, 24-hour access) and low cost (once the system is developed), technology-based programs are more effective in providing information and coaching/support than conventional program. Researchers also indicated their effectiveness in approaching isolated/ marginalized people with stigmatized conditions and underserved populations in communities. These marginalized groups report greater interest in e-health than their more affluent counterparts. In Preliminary Studies (PSs), Asian Americans preferred technology-based programs to traditional programs due to its high accessibility and anonymity. Furthermore, Internet use by Asian Americans is greater than that of any other racial/ethnic group, and over 93% of women are internet users.

Despite the strengths of technology-based programs, few technology-based interventions are available for breast cancer survivors, especially in pain and depressive symptom management. Little is known about the efficacy of culturally tailored technology-based interventions in improving pain and symptom experience of racial/ethnic minority cancer survivors, especially ABD. Only eight programs were identified in an extensive literature review. Two targeted individuals. One program had four face-to-face group sessions. Two programs combined face-to-face meetings with individual telephone counseling. One used a telephone conference approach. Two programs came from our own research team: one aimed to enhance general breast cancer survivorship experience (e.g., needs for help) by providing Web-based information and coaching/support (TICAA), and the other was CAPA that is the basis for CAI. CAPA has multiple unique features based on the actual data from PSs, which are rarely incorporated into technology-based interventions. Also, CAPA is the only existing technology-based program for cancer pain management that is culturally tailored to Asian American breast cancer survivors. However, CAPA rarely considers depressive symptoms accompanying pain in its design or components, and PSs indicated the necessity of further individualization of its components due to diversities in the needs of ABD. For instance, individual ABD selectively used only the specific online educational modules and resources that they were interested in.

CAI will offer the following features that have rarely been used in existing programs. First, CAI incorporates survivors' own cultural attitudes (deep tailoring) based on the actual data from PSs and uses multiple languages (surface tailoring). Indeed, cultural tailoring is essential in providing information and coaching/support for ABD because of their unique cultural heritage (e.g., Confucianism, stigma attached to breast cancer and depression, stoicism to pain). The use of multiple languages is also essential in providing information and coaching/ support to ABD who may not otherwise understand the material and instructions they are given. The feedback from community gatekeepers and ABD will be continuously incorporated into CAI as a part of the continuous cultural tailoring process. The impact of deep and surface tailoring will be differentiated in the dose-response analysis process (see Fidelity).

Second, the individual optimization functionality that will be developed in R61 Phase is unique because it allows further individualization of the intervention components for individual users through a machine-learning method (Genetic Algorithm). Through this functionality, CAI can deliver the most relevant and effective information and coaching/support to each participant. Because there exist diversities in ABD's needs for pain and depressive symptom management even within the same sub-ethnic group, this individualization is necessary; in PSs, ABD selectively used only those components that they were interested in.

Third, CAI is unique in incorporating both group (interpersonal level of influence) and individual (individual level of influence) coaching/support by culturally matched bilingual healthcare providers. There exist added benefits to protocols that include both group and individual coaching/support. Culturally matched bilingual interventionists could also ensure efficacy in coaching/support, limit the potential for harmful communications, provide reliable and objective information/resources, moderate and monitor liability or risk management issues, and nurture a positive group culture in culturally appropriate and sensitive ways.

Fourth, peer support through a social media function (interpersonal level of influence) is rarely used in existing programs. While social media as a health tool is understudied, findings indicate its effectiveness in providing information and coaching/support to breast cancer survivors including racial/ethnic minorities.

Finally, few existing programs incorporated existing evidence-based educational content from scientific authorities. Yet, the accuracy and credibility of information provided by technology-based programs are important aspects that the users are mostly concerned about.

In summary, this study will fill the gap in existing pain management programs for Asian American breast cancer survivors, especially for ABD, and fundamentally enhance the methodology/paradigm related to culturally tailored technology-based programs to reduce health disparities in cancer pain experience among racial/ethnic minority cancer survivors. The design and methods of the program could be easily extended to other sub-ethnic or racial/ethnic groups.

03

Conditions studied

  • Cancer of Breast
  • Depressive Symptoms
  • Cancer Pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women aged 18 years and older who identify as Chinese, Korean, or Japanese;
  • have had a breast cancer diagnosis in the past;
  • can read and write English, Mandarin (simplified or traditional), Korean, or Japanese;
  • have access to the internet through computers or mobile devices (mobile phones and tablets);
  • have experienced cancer pain during the past week (at least 1 on a scale from 0 to 5 [no symptom=0, mild symptom that does not bother=1, somewhat bothering symptom=2, moderate symptom=3, severe symptom=4, and worst possible symptom=5]);
  • have experienced depressive symptoms during the past two weeks (1 to 10 on the Patient Health Questionnaire) which is equivalent to the cut-point of minimal to moderate depression.

Exclusion criteria

Exclusion Criteria:

  • less than 18 years old because their cancer experience would be different from that of adults.
  • Those who are in treatment or not in treatment, but who were diagnosed with breast cancer within the past five years, will be excluded.
  • Those who participated in the PI's pilot studies will be excluded.
  • The participants of R33 phase will exclude those in active depression treatment regardless of their level of depression.
  • Those without Internet access will be excluded, but those with Internet access through community/group computers will be included.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    CAI: Web App-based, individualized coaching and support program for cancer pain

    Web App-based information and coaching/support program for cancer pain management with the individual optimization functionality

    Behavioral: CAI

  • Active comparator
    CAPA: Web App-based information and coaching/support program for cancer pain

    Web App-based information and coaching/support program for cancer pain management

    Behavioral: CAPA

Interventions

  • BehavioralCAI

    Web App-based information and coaching/support program for cancer pain management with additional components for the individual optimization functionality

  • BehavioralCAPA

    Web App-based information and coaching/support program for cancer pain management

06

What researchers measure

Primary outcomes

  1. Cancer Pain Management (CPM)

    1 yes/no question on if cancer pain is managed. If yes, additional questions on cancer pain management (types \[e.g., acetaminophen, NSAIDs, opioid, massage, acupuncture, acupressure, etc.\] and frequency of management \& how much relief). If no, what are the reasons.

    Time frame: Pretest, Post 1-month, Post 3-months

  2. Brief Pain Inventory-Short Form (BPI-SF)

    15 items: (a) a global yes or no item asking for a comparison of pain with other minor aches/pains; (b) 4 items (0\~10) for the sensory component; (c) 1 item for pain medications; (d) a numerical scale rating the effectiveness of pain relief; (e) 7 items (0\~10) for a reactive dimension; and (f) a body diagram for location of pain. The BPI-SF pain scores are determined by adding 4 items on the intensity of pain and 7 items on the interference of pain (0\~110; no pain to extreme pain).

    Time frame: Pretest, Post 1-month, Post 3-months

  3. Activity monitoring device (Fitbit) as a tool for digital pain biomarkers

    * Records continuous, automatic, wrist-based resting heart rates, total steps and time (physical activity), and non-walking activities (e.g., swim duration and pool lengths). * Has an auto sleep tracking function and records the duration of sleep, sleep stage, and number of times waking. Data on the time asleep and number of wakes will be measured and the time asleep (the overall tracked time - the time awake/restless) will be calculated. * The data on resting heart rates, total steps and time (physical activity), and time asleep will be used for data analyses to address the specific aims.

    Time frame: Pretest, Post 1-month, Post 3-months

  4. Memorial Symptom Assessment Scale-Short Form (MSAS-SF)

    * 26 items on symptoms experienced during the past 7 days. * Rated on a 5-point (0-4) Likert scale; (0=no symptom to 4=very much). * Includes the Global Distress Index (4 psychologic and 6 physical symptoms), the physical symptom distress score (12 items), the psychologic symptom distress score (6 items), the total symptom distress, and the number of total symptoms. * Determines the MSAS-SF scores by adding the ratings for distress of 26 symptoms.

    Time frame: Pretest, Post 1-month, Post 3-months

  5. Center for Epidemiologic Studies Depression Scale (CES-D)

    * Measures the frequency of depressive symptoms in the past week. * 20 items on the level of depression (range=0\~60). All items are summed to calculate depressive symptoms score

    Time frame: Pretest, Post 1-month, Post 3-months

  6. Functional Assessment of Cancer Therapy Scale-Breast Cancer (FACT-B)

    * 44-items to measure multidimensional quality of life in patients with breast cancer. * Consists of the FACT-General plus the Breast Cancer Subscale (BCS), which complements the general scale with items specific to quality of life. * 7 domains: physical well-being, social/family well-being, emotional well-being, functional well-being, relationship with doctor, BCS, and additional concerns. * On a 5-point Likert scale (0=not at all\~4=very much), indicating a range of non to extreme interference. All items are summed to obtain a total score (FACT-B score).

    Time frame: Pretest, Post 1-month, Post 3-months

Secondary outcomes

  1. Questions on Attitudes and Perceived Barriers

    6 items on attitudes (bipolar \[-3 to +3\] scales), 16 items on perceived barriers (4-point Likert scales). By summing the items in each subscale, the attitude and perceived barriers scores will be calculated.

    Time frame: Pretest, Post 1-month, Post 3-months

  2. Cancer Behavior Inventory (CBI)

    * A measure of self-efficacy for coping with cancer. * 27-items (9-point scale) on how confident to accomplish certain behaviors (not at all=1, to totally confident=9). By summing the items, the self-efficacy scores will be calculated.

    Time frame: Pretest, Post 1-month, Post 3-months

  3. Questions on Social Influence

    Data from 3 items measured on 7-point Likert scales will be summed to calculated the social influence scores.

    Time frame: Pretest, Post 1-month, Post 3-months

  4. Disease Factors

    7 questions on disease factors, including general health, diagnosis of breast cancer, length of time since diagnosis, cancer type (if known), stage of cancer, diagnosed clinical depression and medical treatments, and medication. Used in PSs 1-4, \& 5 without any issues.

    Time frame: Pretest, Post 1-month, Post 3-months

  5. Genetic factors

    Questions on family history of depression and psychiatric diseases. 4 questions on family history of depression and other psychiatric diseases only among first-degree relatives (yes or no) and among other relatives (yes or no).

    Time frame: Pretest, Post 1-month, Post 3-months

  6. Social Readjustment Rating Scale (SRRS)

    • 57 items on life events (e.g., death, marriage, empty nest, etc.), giving different weighting depending on the severity of the stressor (0 to 100).

    Time frame: Pretest, Post 1-month, Post 3-months

  7. Acculturation Stress Scale (ASS)

    5 questions on the level of acculturation (on a 5-point Likert scale; 1 = exclusively own sub-ethnic group, 5 = exclusively American) in foods, music, customs, close friends, and language (only when the country of birth is not the U.S.).

    Time frame: pretest, Post 1-month, Post 3-months

  8. Personal Resources Questionnaire (PRQ-2000)

    * 15 items measuring perceived level of social support. * Includes 7-point Likert scale items in 5 dimensions: (a) provision for attachment/ intimacy; (b) social integration; (c) opportunity for nurturing behavior; (d) reassurance of worth; and (e) the availability of informational, emotional, and material help.

    Time frame: pretest, Post 1-month, Post 3-months

  9. Discrimination Scale (DS)

    • 9 items (6-point Likert scale) on discrimination experience \& 1 question on perceived reasons for discrimination 198 (1=ancestor/national origin; 2=gender; 3=race; 4=age; 5=height; 6=skin color; 7=sexual orientation; 8=weight; 9=income or educational level; 10=others).

    Time frame: pretest, Post 1-month, Post 3-months

  10. Perceived Isolation Scale (PIS)

    PIS measures perceived interactions (social isolation) and includes 6 items on social support and 3 items on interactions/loneliness (3-point Likert scales). The average of the items is calculated as the interaction scores.

    Time frame: pretest, Post 1-month, Post 3-months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Aug 2027, 42 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 42 months is above that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

Completion moved once since we started tracking on Sep 25, 2026: Aug 2027 → Mar 2028, on Oct 30, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2023
First posted
Oct 16, 2023
StartActual
Feb 20, 2024
Primary completionEst.
Aug 31, 2027
CompletionEst.
Mar 31, 2028was Aug 2027
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Vanderbilt University · Nashville, United States
Show 1 removed
  • The University of Texas at Austin · Austin, United States
Oct 30, 2026
Study completion
Aug 31, 2027→Mar 31, 2028
Oct 30, 2026
Contact
Study contact changed: c•••@austin.utexas.edu · •••2142→c•••@vanderbilt.edu · •••8439; removed r•••@utexas.edu · •••2877. See the current contact
Oct 30, 2026
Sponsor
University of Texas at Austin→Vanderbilt University
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    1 site added, 1 site removed
    Show site
    • Vanderbilt University · Nashville, United States
    Show 1 removed
    • The University of Texas at Austin · Austin, United States
    Study completion Aug 31, 2027→Mar 31, 2028
    Sponsor University of Texas at Austin→Vanderbilt University
    Contact Study contact changed: c•••@austin.utexas.edu · •••2142→c•••@vanderbilt.edu · •••8439; removed r•••@utexas.edu · •••2877. See the current contact
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06085313
Responsible party
Eun-Ok Im (Professor, Vanderbilt University) — Principal investigator
First posted
Oct 16, 2023
Start date
Feb 20, 2024
Primary completion
Aug 31, 2027 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Oct 30, 2026

Study contacts

Wonshik Chee, PhD
Contact
cai.help@vanderbilt.edu
615-343-8439
Eun Ok Im, PhD, MPH
principal investigator · Vanderbilt University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion